FDA Approves Merck's Winrevair for Rare Lung Disease

The groundbreaking treatment targets the underlying cause of pulmonary arterial hypertension, offering new hope to patients.

The FDA has approved Merck's Winrevair for the treatment of pulmonary arterial hypertension (PAH), a rare and potentially fatal lung disease.
Winrevair is the first drug to target the underlying cause of PAH, aiming to improve patients' quality of life by reducing disease progression and mortality.
The drug, administered as an injection every three weeks, showed significant improvements in exercise capacity and reduced the risk of death in clinical trials.
Merck acquired the drug through its $11.5 billion purchase of Acceleron Pharma in 2021, marking a significant step in its strategy to focus on rare diseases.
Winrevair will be available in the U.S. by the end of April, priced at $14,000 per vial, with Merck offering financial assistance programs for eligible patients.